<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>secondary iron overload &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/secondary-iron-overload/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Sat, 24 Oct 2026 21:28:23 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.1.3</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>secondary iron overload &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Acid-Blocking Drug Plus Iron Chelator Shows Added Effect on Iron Overload in Hereditary Anaemias</title>
		<link>https://bioengineer.org/acid-blocking-drug-plus-iron-chelator-shows-added-effect-on-iron-overload-in-hereditary-anaemias/</link>
		
		<dc:creator><![CDATA[]]></dc:creator>
		<pubDate>Sat, 24 Oct 2026 21:28:23 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[cross-over trial]]></category>
		<category><![CDATA[deferasirox]]></category>
		<category><![CDATA[esomeprazole]]></category>
		<category><![CDATA[hepcidin]]></category>
		<category><![CDATA[hereditary anaemias]]></category>
		<category><![CDATA[intestinal iron absorption]]></category>
		<category><![CDATA[iron chelation]]></category>
		<category><![CDATA[liver iron concentration]]></category>
		<category><![CDATA[proton pump inhibitors]]></category>
		<category><![CDATA[re-analysis]]></category>
		<category><![CDATA[secondary iron overload]]></category>
		<category><![CDATA[thalassaemia]]></category>
		<guid isPermaLink="false">https://bioengineer.org/?p=452355</guid>

					<description><![CDATA[A re-analysis of a placebo-controlled cross-over trial suggests that combining the proton pump inhibitor esomeprazole with the iron chelator deferasirox reduced liver iron concentration in patients with non-transfusion-dependent hereditary anaemias, whereas neither drug achieved this alone, though the small stratified subgroups warrant cautious interpretation.]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">452355</post-id>	</item>
	</channel>
</rss>
